On February 4, 2025, the Health Technologies Division of our team, I-SENSE GROUP, took part in the event ‘Fostering Synergies to Beat Cancer: The Impact of EU-funded Projects’, organised by the European Health and Digital Executive Agency (HaDEA) in Brussels. The event served as a showcase for cancer-related projects managed by HaDEA under Horizon Europe’s Cancer Mission and the EU4Health programme. Its primary goal was to foster collaboration and synergies between these initiatives, NGOs, health organisations working in the field of cancer, National Contact Points and National Focal Points and policy makers, enhancing their collective impact on cancer research, prevention, and treatment.
As a key player in cancer-related research and technology development, I-SENSE GROUP is actively involved in four major projects addressing various aspects of cancer care and innovation:
- Two ongoing projects, ONCOSCREEN and ONCODIR, where I-SENSE GROUP plays a crucial role as technical manager, leading the development of cutting-edge technologies for early cancer detection, prevention and precision medicine.
- Two upcoming projects, which are set to commence soon, further expanding our team’s commitment to advancing cancer research. Notably, I-SENSE GROUP is leading the coordination of one of these projects, reinforcing its role as a key innovator in the field.
Representing I-SENSE GROUP at the event, our Dr. Dimitra Dionysiou, Team Leader of the Health Technologies Division, engaged with stakeholders from various EU-funded projects, exchanging insights and exploring potential collaborations to maximize the impact of ongoing and future research efforts.
Participation in this event highlights I-SENSE GROUP’s strong commitment to cancer research, leveraging advanced technologies and interdisciplinary expertise to contribute to the fight against cancer. The organisation remains at the forefront of innovation, actively shaping the future of healthcare through EU-funded initiatives.
Stay tuned for more updates on I-SENSE GROUP’s contributions to cancer research and innovation.
